Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: A comprehensive systematic review

B Jayathilaka; F Mian; J Cockwill; F Franchini; G Au-Yeung; M IJzerman

Journal article

Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: A comprehensive systematic review

B Jayathilaka, F Mian, J Cockwill, F Franchini, G Au-Yeung, M IJzerman

Critical Reviews in Oncology/Hematology | Elsevier | Published : 2025

DOI: 10.1016/j.critrevonc.2024.104601

Abstract

Background: Immune-related adverse events (irAE) pose challenges to the use of immune checkpoint inhibitors (ICI). While risk factors for irAE are emerging, most studies are small, retrospective analyses that seldom report on diverse cancers or rare irAE. This paper reports a systematic review that summarises literature on irAE risk factors across cancers and proposes a categorisation approach. Method: A systematic search was conducted in Medline OVID, Embase and Web of Science databases following PRISMA guidelines (CRD42022310127). Original research published in peer-reviewed journals between January 2017-Decmeber 2021 were selected. Eligible studies included patients with any cancer and ev..

View full abstract

University of Melbourne Researchers

Fanny Franchini Author

George Au-Yeung Author

Maarten IJzerman Author

Related Projects (3)

Collaboration Agreement for Value Based Healthcare Project 5.2 Immuno-oncology related adverse events: feasiblity of risk prediction in clinical practice.

Value Based Healthcare Program

PRedicting the population health economic IMpact of current and new CAncer Treatments (PRIMCAT)

Dr Fanny Franchini and Professor Maarten IJzerman, together with colleagues in the University of Melbourne, the University of New South Wale..

Grants

Funding Acknowledgements

The authors would like to thank Faiza Hoda, Mandy Lin and Teresa Nguyen for assisting with screening of studies. This study is part of graduate research supported by an Australian Government Research Training Program (RTP) Scholarship and was supported by funding from the Victorian Comprehensive Cancer Centre Alliance as part of the Strategic Program Plan 2021-2024.